Skip to search formSkip to main contentSkip to account menu

GR 144053

Known as: GR-144053, GR144053 
National Institutes of Health

Related topics

Related topics

3 relations
GR144053F

Broader (2)

PiperazinesPiperidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2000
2000
Lack of tPA Significantly Affects Antithrombotic Therapy by a GPIIb/IIIa Antagonist, but not by a Thrombin Inhibitor in Mice
Summary The interaction of fibrinolytic components with platelets or coagulation factors after endothelial injury, was… 
2000
2000
tPA, but not uPA, significantly affects antithrombotic therapy by a glycoprotein IIb/IIIa antagonist, but not by a factor Xa inhibitor.
To define the interaction of fibrinolytic components with platelets or coagulation factors on thrombus formation, we investigated… 
1999
1999
Comparison of the antithrombotic effects and bleeding risk of fractionated aurin tricarboxylic acid and the GPIIb/IIIa antagonist GR144053 in a hamster model of stenosis.
1998
1998
Effect of GR144053, a fibrinogen-receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tPA in the injured carotid artery of the hamster.
The antithrombotic effect of GR144053, which inhibits platelet aggregation by binding to the fibrinogen receptor (glycoprotein… 
1996
1996
Biochemical characterization of a new disintegrin, flavostatin, isolated from Trimeresurus flavoviridis venom.
1996
1996
The composition of the platelet cytoskeleton following activation by ADP: effects of various agents that modulate platelet function.
Platelet activation by adenosine diphosphate (ADP) results in changes in the composition of the large cytoskeletal fragments that… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)